Published: 13:30 CET 07-11-2014 /GlobeNewswire /Source: MDxHealth (R) / : MDXH /ISIN: BE0003844611
MDxHealth's new share capital amount and new number of shares
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW
IRVINE, CA, and HERSTAL, BELGIUM - November 7, 2014 - MDxHealth SA (Euronext Brussels: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today, in conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that further to the capital increase that was completed on Friday, November 7, 2014, its share capital has increased from € 27,321,762.02 to € 30,053,884.52 and the number of issued and outstanding shares have increased from 34,251,303 to 37,676,303, through the issuance of 3,425,000 new shares.